Lab testing as unique as your needs.
CIAN Diagnostics is a premier full-spectrum organization, offering state-of-the-art, turn-key high-throughput COVID-19 sample collection, sample transport, sample testing, and sample reporting services to clients across the country via 2 core facilities, multiple satellite locations, and full-service mobile testing units, and extensive widely dispersed collection teams managed from a central command center. The organization is 100% minority-owned, with a majority of our partners and vendors being minority-owned organizations as well. CIAN Diagnostics has held continuous CLIA certification since 2014, operates 24/7, is staffed by over 100 employees, and comprises 60,000 sq ft of laboratory and logistical space supported by an additional 60,000 sq ft of warehouse space, allowing us to maintain an industry-leading turnaround time of 24 hours or less, regardless of where in the country the samples were collected. We maintain a multilingual customer support call center that operates 16 hours a day, 7 days a week. CIAN is well-positioned to meet all the needs outlined in the request for proposal and will respond to each task identified.
CIAN Diagnostics has been a trusted partner of local, county, and state governments since the beginning of the pandemic response. We have supported, and continue to support, over 250 schools, school districts, and universities across the country, as well as long-term care facilities, correctional facilities, community-based testing sites, and individual employers complete with on-site collection support staff and COVID-19 testing personnel. CIAN Diagnostics has shown itself time and again to be nimble, creative, robust, responsive, economical, and above all else, successful, even under the most challenging conditions. Because of this passionate approach to delivering the highest quality services, CIAN Diagnostics has a well-established track record of successfully supporting a wide array of COVID-19 testing programs. Working in parallel with multiple states’ COVID-19 Task Forces, CIAN Diagnostics has been a key strategic partner in at least 10 major COVID-19 testing initiatives, demonstrating our operational strength by conducting over 3 million individual COVID-19 RT-PCR and Rapid Antigen tests.
Dr. Jackson Snyder, MD, PhD, JD
With over twenty-five years of experience in medicine, law, and research, Dr. Snyder currently serves as Laboratory Director for CIAN Diagnostics. Dr. Snyder evaluates and develops new business partnerships, provides medical & scientific leadership, direction, and consultation, authors and reviews non-clinical, clinical, and regulatory documents, monitors & designs clinical trials, develops regulatory strategies, and trains clinical research professionals, in addition to his duties as Laboratory Director. Dr. Snyder taught law, medicine, regulatory science, and forensic science at Thomas Jefferson, George Washington & Johns Hopkins Universities and is a Fellow of the Association of Clinical Research Professionals, the American College of Medical Toxicology, the American Academy of Clinical Toxicology, the Academy of Toxicological Scientists, the Association of Clinical Scientists, the American Society of Clinical Pathologists, the College of American Pathologists, the Academy of Physicians in Clinical Research, the National Academy of Clinical Biochemistry, the American Board of Quality Assurance & Utilization Review, and the American College of Legal Medicine.
Dr. Mitchell Burken, MD, MPP
VP of Clinical Affairs
Dr. Burken has extensive experience in the intersection of public policy, biotechnology/science, and healthcare. He currently serves CIAN Diagnostics as the VP of Clinical Affairs where he provides correlative care consultations on all infectious disease molecular products as well as assists with laboratory validation procedures and processes. At the Department of Veteran’s Affairs, Dr. Burken served in the areas of laboratory management, technology evaluation, quality improvement, and epidemiology. Dr. Burken worked in the Coverage & Analysis Group, developing National Coverage Determinations (NCDs), with an emphasis on emerging diagnostic devices for the Medicare program. Dr. Burken worked extensively and collaboratively with key stakeholders on various matters of medical policy and found practical solutions for the adoption and reimbursement of advanced technologies such as emerging laboratory diagnostics.
Dr. Eric Allely, MD
Chief Operating Officer
Dr. Eric Allely has decades of leadership experience in both the military and private sectors. Dr. Allely completed his surgical residency at Washington Hospital Center in Washington, D.C. and directed the Center of Medical Education Technologies at the Henry Jackson Foundation for 10 years, where he led the design, development, and deployment of multiple computer-based training systems. As the Maryland National Guard State Surgeon, Dr. Allely led the COVID-19 Task Force for COVID-19 testing involving all 225 nursing homes in the state in 2020.
Dr. Allely has extensive military medical experience including unit leadership, academic appointments, development of education and training programs, operational research, and combat deployments. He served as a Task Force Surgeon in Iraq, where he evaluated health threats, assisted the Iraqi Ministry of Health to assess medical system capabilities and provided direct medical care. Dr. Allely has public and private sector leadership in the design, development, and deployment of computer-based training systems, connectivity tools for bi-directional information exchange between medical information systems, and clinical decision support tools for clinical pathology interpretations. He has conducted research and analysis in support of medical policies, doctrine, and operational plans in service, and joint and interagency settings.
Dr. Allely has led the development of analytic products at all classification levels. He is the primary author and lead on multiple senior-level briefings to Department of Defense (DoD) and interagency partners, including U.S. Joint Forces Command (USJFCOM), U.S. Northern Command (USNORTHCOM), Department of State, Department of Homeland Security, Department of Health and Human Services, Central Intelligence Agency, National Security Agency, National Counter-Terrorism Center and the National Security Council.
Dr. James McArdle, Ph.D., MBA, PMP
Chief Scientific Officer
Dr. James McArdle is a leader in the biotechnology, infectious diseases, molecular diagnostics, and vaccine R&D/manufacturing spaces. He is a seasoned scientist with extensive creative, technical, execution, and management experience in both the public and private sectors that brings decades of innovation and expertise to CIAN Diagnostics. Dr. McArdle draws on a wide expertise base, which includes successfully managing large (>70) multi-disciplinary groups of people (both in the U.S. and overseas), P&L responsibility, $100M projects and project portfolios, and simultaneous product development efforts. Dr. McArdle is a Department of Defense-certified Project/Program Manager with over 25 years of experience developing, validating, and deploying molecular diagnostics for the detection of infectious diseases and biothreat agents.
For much of his career, Dr. McArdle directed $5M-141M programs in infectious disease, biothreat detection and countermeasure development, validation, manufacturing, and distribution for the National Institute of Allergy and Infectious Diseases (NIAID), Navy, Air Force, and the Office of the Secretary of Defense (OSD). Dr. McArdle was a member of the kick-off and leadership team and Principal Program Manager for the $900M U.S. Army Medical Material Agency (USAMMDA) Medical Product Research and Development IDIQ contract.
Dr. McArdle has set up de novo molecular laboratories across the globe for the U.S. Department of Defense for countering bioterrorism and detecting infectious disease agents. His engagements have included the National Institutes of Health, Human Genome Sciences, the American Type Culture Collection (ATCC), the U.S. Navy, the University of Maryland at College Park, and the University of Virginia.
Olena Lar, Ph.D.
Dr. Olena Lar has over 18 years of post-doctoral and project management expertise in molecular genetics, DNA and protein engineering, protein expression, PCR analysis, ELISA, assay development and validation, and sequencing. Dr. Lar heads the SARS-CoV-2 variant sequencing project at CIAN and has been instrumental in bringing together technologies to make sequencing available at costs affordable to even developing countries.
Sam Mullapudi, BS
Principal, CIAN Diagnostics
Mr. Mullapudi has over 23 years of Bio-Pharmaceutical industry experience in Good Manufacturing Practices (GMP) Quality Control, Analytical Biotechnology, and Research and Development departments. He earned a BS in Pharmacy and has extensive management expertise in Analytical Quality & Logistics and Lab Operations at AstraZeneca/Medimmune. He currently serves as Principal at CIAN Diagnostics and is responsible for all capital management, business development, daily operations, budget, and contracts management.
Ross Eichberg Comes to CIAN Diagnostics with over 3 decades of transactional healthcare experience including joint ventures, laboratory reference agreements, managed services agreements, physician agreements, hospital and health system contracts, pharmacy development and sales, product distribution, data and IP protection, and compliance program development and implementation. For the past decade, Ross has led all aspects of a global portfolio of companies’ legal functions and was instrumental in the management and growth of this international portfolio which is focused on pharmacogenomic and COVID testing, healthcare and information technology, cloning, pharmacy, medical devices, and biologics.
Chief Compliance Officer
Ashley Graham is a Certified Compliance Professional with diverse experience in highly regulated industries. She brings a substantial background in consultative services and building relationships at all levels of the organization to drive program awareness and its importance to the business and strategic goals. Ashley also brings to CIAN her knowledge of ever-changing best practice standards, and federal and state regulations, and is recognized for exercising sound judgment, behaving with integrity, being highly adaptable to new situations and assignments, and successfully mentoring others.
CIAN Diagnostics is committed to providing attentive customer service. We are happy to answer any questions you may have about our testing options.